For this, we initiated Yumm2.1 tumors in UVR animals and treated them with anti-PD-1 and anti-CD25, an antibody that depletes systemic CD25+ cells which are primarily present at high levels in Tregs, which can modestly reduce tumor growth by depleting Tregs in murine melanoma models.30 Here, PDCD1 is linked to melanoma.